Primary Peritoneal Carcinoma Completed Phase 2 Trials for Cefotaxime (DB00493)

IndicationStatusPhase
DBCOND0028874 (Primary Peritoneal Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs